Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: Role of golgi apparatus

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 3035-3042

  Fabbri, Francesco ^a   Zoli, Wainer ^a   Carloni, Silvia ^a   Ulivi, Paola ^a   Arienti, Chiara ^a   Brigliadori, Giovanni ^a   Montanari, Marco ^b   Tesei, Anna ^a   Silvestrini, Rosella ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTHRACYCLINE; CASPASE 2; CASPASE 3; CASPASE 8; DOXORUBICIN; FAS ANTIGEN; GANGLIOSIDE GD3;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; GOLGI COMPLEX; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ANTHRACYCLINES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRIDGED COMPOUNDS; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; GANGLIOSIDES; GOLGI APPARATUS; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 80051947740     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22654     Document Type: Article

References (28)

1. Arancia G, Calcabrini A, Meschini S, Molinari A. 1998. Intracellular distribution of anthracyclines in drug resistant cells. Cytotechnology 27: 95-111.
2. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. 1989. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23: 81-86.
3. Bour-Dill C, Gramain MP, Merlin JL, Marchal S, Guillemin F. 2000. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry 39: 16-25.
4. de Wit R. 2008. Chemotherapy in hormone-refractory prostate cancer. BJU Int 101: 11-15.
5. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
6. Drummond DC, Zignani M, Leroux J. 2000. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39: 409-460.
7. Ferri KF, Kroemer G. 2001. Organelle-specific initiation of cell death pathways. Nat Cell Biol 3: E255-E263.
8. Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJ, Schmidt PG, Krasieva TB, Shimizu S, Tromberg BJ. 1996. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res 56: 2066-2075.
9. Hicks SW, Machamer CE. 2005. Golgi structure in stress sensing and apoptosis. Biochim Biophys Acta 1744: 406-414.
10. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. 1993. Comparison of the cardiotoxic effects of liposomal doxorubicin versus free doxorubicin in beagle dogs. In Vivo 7: 17-26.
11. Maag RS, Hicks SW, Machamer CE. 2003. Death from within: Apoptosis and the secretory pathway. Curr Opin Cell Biol 15: 456-461.
12. Malisan F, Testi R. 2002. GD3 ganglioside and apoptosis. Biochim Biophys Acta 1585: 179-187.
13. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
14. Molinari A, Calcabrini A, Meschini S, Stringaro A, Del Bufalo D, Cianfriglia M, Arancia G. 1998. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 75: 885-893.
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M. 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
16. Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM. 1988. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6: 517-526.
17. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE. 2004. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: An open-label, single-dose study. Cancer Chemother Pharmacol 54: 514-524.
18. Petrioli R, Fiaschi A, Francini E, Pascucci A, Francini G. 2008. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone refractory prostate cancer. Cancer Treat Rev 34: 710-718.
19. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
20. Pienta KJ, Smith DC. 2005. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 55: 300-318.
21. Rippo MR, Malisan F, Ravagnan L, Tomassini B, Condo I, Costantini P, Susin SA, Rufini A, Todaro M, Kroemer G, Testi R. 2000. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. FASEB J 14: 2047-2054.
22. Rivinoja A, Hassinen A, Kokkonen N, Kauppila A, Kellokumpu S. 2009. Elevated Golgi pH impairs terminal N-glycosylation by inducing mislocalization of Golgi glycosyltransferases. J Cell Physiol 220: 144-154.
23. Safra T. 2003. Cardiac safety of liposomal anthracyclines. Oncologist 8: 17-24.
24. Shelley M, Harrison C, Coles B, Stafford J, Wilt T, Mason M. 2006. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 4: CD005247.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
26. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
27. Thierry AR, Vigé D, Coughlin SS, Belli JA, Dritschilo A, Rahman A. 1993. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 7: 572-579.
28. Wlodkowic D, Skommer J, McGuinness D, Hillier C, Darzynkiewicz Z. 2009. ER-Golgi network-A future target for anti-cancer therapy. Leuk Res 33: 1440-1447.